**Summary**
EMV Capital PLC, a deep tech, life sciences, and sustainability venture capital investment group, released a trading and portfolio update for the year ended 31 December 2025. The company reported strong operational and portfolio performance, with total Assets Under Management (AUM) exceeding ยฃ100 million. Key highlights include
1. **Operational Growth**Scaling of the core venture capital platform, increased AUM, and strengthened revenue streams.
2. **Portfolio Support**Syndicated fundraisings totaling ยฃ12.0 million across 14 portfolio companies, and advancement of the Venture Building program, generating ยฃ10.4 million in fair value creation.
3. **Strategic Acquisitions**Acquisition of XF-73 intellectual property and clinical assets from Destiny Pharma Limited, forming AMR Bio Limited.
4. **Financial Performance**Group revenue grew by 16% to ยฃ2.8 million, driven by higher corporate finance fees and increased fundraising activity. EMV Capital core revenue increased to ยฃ3.2 million, covering a significant portion of operating costs.
5. **Portfolio Highlights**Notable progress in portfolio companies like Wanda Health, EpiBone, AMR Bio, Deeptech Recycling Technologies, Sofant Technologies, Q-Bot, and Martlet Capital, with successful fundraisings, strategic milestones, and value creation.
Despite challenging market conditions, EMV Capital remains focused on disciplined capital deployment, proactive portfolio management, and scaling its platforms. The company is well-positioned to navigate market uncertainty and benefit from a recovery in capital markets.
Below is the HTML table code comparing the financials and debt year-on-year based on the provided text:
### Notes:
1. **AUM**: The 2025 figure is stated as "in excess of ยฃ100 million," so the change is calculated based on the minimum increase.
2. **Revenue and Cash Figures**: Approximate values are denoted with "~" as per the text.
3. **Syndicated Fundraisings and Portfolio Companies**: Direct year-on-year comparisons are provided based on the given data.
4. **Quoted Securities**: The decrease reflects the reduction in readily realisable quoted securities held by the Group. This table provides a clear comparison of key financial and operational metrics between 2024 and 2025.